Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Completes Acquisition of CRI

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Caliper Life Sciences today said that it has completed the acquisition of privately held Cambridge Research & Instrumentation for approximately $20 million.

Caliper announced the deal to acquire the Woburn, Mass.-based firm two weeks ago. The acquisition expands Caliper's life sciences tools portfolio in clinical research, pathology, and clinical market applications.

Caliper paid approximately $7.9 million in cash, $10.3 million in stock, and assumed around $1.8 million of debt. The common stock portion included issuing around 1.6 million shares of its common stock.

"CRi's products provide an entry point for Caliper to address the expanding billion-dollar tissue imaging and digital pathology clinical research market," Caliper President and CEO Kevin Hrusovsky said in a statement. "In addition, CRi's technologies enhance our toolkit of proprietary technologies for creating new product solutions to advance our vision to transform 'sick care' to 'health care' through next-generation biomarker discovery, patient stratification studies, and companion diagnostics for personalized medicine."

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.